Forte Biosciences (FBRX) awards 18,353 RSUs to director Steven Kornfeld

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Kornfeld Steven reported acquisition or exercise transactions in this Form 4 filing.

Forte Biosciences, Inc. director Steven Kornfeld received a grant of restricted stock units as equity compensation. He was awarded 18,353 RSUs, each representing one share of common stock at a price of $0.00 per unit. Following this award, he holds 18,353 RSUs directly.

According to the grant terms, 100% of these RSUs will vest on the date of the first annual stockholder meeting that occurs after May 29, 2026, provided he continues as a Service Provider under the company’s 2021 Equity Incentive Plan through that date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kornfeld Steven

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	18,353	$0.00	--

Holdings After Transaction: Restricted Stock Units — 18,353 shares (Direct, null)

Footnotes (1)

Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock. Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026.

Key Figures

RSUs granted: 18,353 RSUs Grant price per RSU: $0.00 per unit Underlying common shares: 18,353 shares +2 more

5 metrics

RSUs granted 18,353 RSUs Grant of restricted stock units on May 29, 2026

Grant price per RSU $0.00 per unit RSU award to director Kornfeld

Underlying common shares 18,353 shares Each RSU equals one share of common stock

Holdings after transaction 18,353 RSUs Total RSUs held directly following the award

Vesting timing First annual meeting after May 29, 2026 100% of RSUs vest on that meeting date if service continues

Key Terms

Restricted Stock Units, RSU, 2021 Equity Incentive Plan, Service Provider

4 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSU financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share"

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

2021 Equity Incentive Plan financial

"as defined in the 2021 Equity Incentive Plan) through such date"

Service Provider financial

"Subject to the Reporting Person's continuing as a Service Provider"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/02/2026 - 04:35 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kornfeld Steven

(Last)

(First)

(Middle)

C/O FORTE BIOSCIENCES, INC.

3060 PEGASUS PARK DR., BUILDING 6

(Street)

DALLAS

TEXAS

75247

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Forte Biosciences, Inc. [ FBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	05/29/2026		A		18,353		⁽²⁾	⁽²⁾	Common Stock	18,353	$0	18,353	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.

2. Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026.

	/s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Forte Biosciences (FBRX) director Steven Kornfeld report on this Form 4?

Steven Kornfeld reported receiving a grant of 18,353 restricted stock units from Forte Biosciences as equity compensation. Each RSU corresponds to one share of common stock and was granted at a price of zero dollars per unit, reflecting a standard stock-based award.

How many Forte Biosciences (FBRX) RSUs were granted to Steven Kornfeld?

Steven Kornfeld was granted 18,353 restricted stock units by Forte Biosciences. Each RSU represents a contingent right to receive one share of Forte common stock, giving him 18,353 underlying shares if all units ultimately vest under the award terms.

What are the vesting conditions for Steven Kornfeld’s Forte Biosciences (FBRX) RSUs?

All 18,353 RSUs vest in a single installment on the date of the first annual stockholder meeting after May 29, 2026. Vesting requires that Kornfeld continue as a Service Provider under Forte’s 2021 Equity Incentive Plan through that vesting date.

What does each Forte Biosciences (FBRX) RSU in this grant represent?

Each restricted stock unit represents a contingent right to receive one share of Forte Biosciences common stock. The units have a stated grant price of zero dollars, reflecting that they are compensation-based awards rather than shares purchased in the open market.

How many Forte Biosciences (FBRX) securities does Steven Kornfeld hold after this RSU grant?

After this RSU grant, Steven Kornfeld holds 18,353 restricted stock units directly. These RSUs are derivative securities tied to Forte Biosciences common stock and will convert into the same number of shares if the vesting conditions are fully satisfied.